Jazz Pharmaceuticals plc — Director's Dealing 2012

Jan 18, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2012-01-18

Reporting Person: COZADD BRUCE C (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-01-18	Common Stock	D	546811	—	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-01-18	Incentive Stock Option (right to buy)	$15.09	D	15902	Disposed	2014-02-17	Common Stock (15902)	Direct
2012-01-18	Incentive Stock Option (right to buy)	$30.18	D	5299	Disposed	2014-02-17	Common Stock (5299)	Direct
2012-01-18	Incentive Stock Option (right to buy)	$45.27	D	5299	Disposed	2014-02-17	Common Stock (5299)	Direct
2012-01-18	Incentive Stock Option (right to buy)	$19.37	D	12583	Disposed	2017-02-26	Common Stock (12583)	Direct
2012-01-18	Incentive Stock Option (right to buy)	$7.96	D	7040	Disposed	2018-05-15	Common Stock (7040)	Direct
2012-01-18	Incentive Stock Option (right to buy)	$1.25	D	182	Disposed	2019-01-20	Common Stock (182)	Direct
2012-01-18	Incentive Stock Option (right to buy)	$11.48	D	17420	Disposed	2020-03-07	Common Stock (17420)	Direct

Footnotes

F1: Disposition made in connection with the conversion of securities in the merger (the "Merger") pursuant to the Agreement and Plan of Merger and Reorganization by and among Jazz Pharmaceuticals plc (formerly Azur Pharma Public Limited Company), Jaguar Merger Sub Inc., Jazz Pharmaceuticals, Inc. and Seamus Mulligan, solely in his capacity as indemnitors' representative. The effective date of the Merger is January 18, 2012. This report is being filed by the Reporting Person solely to report the disposition of securities of Jazz Pharmaceuticals, Inc. made in connection with the Merger. The Reporting Person will file a separate Form 4 to reflect the corresponding acquisition of securities of Jazz Pharmaceuticals plc made in connection with the Merger.

F2: Shares of common stock converted in connection with the Merger into an equal number of ordinary shares of Jazz Pharmaceuticals plc having a market value, based on the closing price of Jazz Pharmaceuticals plc's ordinary shares on the effective date of the Merger, of $47.34 per share.

F3: This option vested one fourth on February 18, 2005, one eighth on August 18, 2005, and the remainder in 30 equal monthly installments thereafter.

F4: This option has a vesting schedule of one third vested on February 27, 2010 and the remainder vesting in 24 equal monthly installments thereafter.

F5: This option has a vesting schedule of one half vested on April 8, 2010 and the remainder vesting in 24 equal monthly installments thereafter.

F6: This option has a vesting schedule of one third vested on January 21, 2010 and the remainder vesting in 24 equal monthly installments thereafter.

F7: This option has a vesting schedule of one fourth vested on March 8, 2011 and the remainder vesting in 36 equal monthly installments thereafter.

F8: Options assumed/converted in connection with the Merger into options to acquire the same number of ordinary shares of Jazz Pharmaceuticals plc at the same exercise price and on substantially the same terms.